Please see below for a message from our colleagues at Novartis and the LSE Medical Technology Research Group (MTRG)
We are currently recruiting patient representatives to participate in a 1.5 day workshop on 12-13 March 2018 at the London School of Economics to evaluate a compounds under clinical development for the treatment of Non-Alcoholic Steatohepatitis (NASH). This project is a partnership between Novartis and the LSE Medical Technology Research Group (MTRG). We would like a patient representative to provide the patient perspective during our discussion. This will provide valuable feedback regarding what are the most detrimental side effects experienced when taking medication to treat NASH, and what are the most important aspects a drug should include to this condition. These views may be incorporated to use as evidence for HTA submission.
Your role as a participant
As a patient representative, your role would be to participate in a discussion with 10-12 experts. These experts will consist of 4-5 clinicians, pharmacists or liver specialists, 4-5 economists (methodologists). The workshop will be a facilitated discussion, where you and the group will review different compounds to treat NASH using multiple value dimensions (e.g. quality of life, adverse side effects, innovation, etc.).
We will provide 1 brief pre-read prior to the conference to provide additional background on NASH and the conference.
Date Monday, 12 March Tuesday, 13 March
Workshop time 15:00-18:45 9:00 - 17:00
19:00 optional dinner
London School of Economics
London WC2A 2AE
Compensation & accommodation
Participants will be compensated for their time.
Accommodation will be offered to participants that are traveling to London for the conference.
Interest in participating or have additional questions, please do not hesitant to reach out to Katie McClain, email@example.com